Annual Accounts Receivable
$105.56 M
+$7.16 M+7.28%
December 31, 2023
Summary
- As of February 7, 2025, PCRX annual accounts receivable is $105.56 million, with the most recent change of +$7.16 million (+7.28%) on December 31, 2023.
- During the last 3 years, PCRX annual accounts receivable has risen by +$52.51 million (+98.99%).
- PCRX annual accounts receivable is now at all-time high.
Performance
PCRX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$100.65 M
-$4.13 M-3.94%
September 30, 2024
Summary
- As of February 7, 2025, PCRX quarterly accounts receivable is $100.65 million, with the most recent change of -$4.13 million (-3.94%) on September 30, 2024.
- Over the past year, PCRX quarterly accounts receivable has increased by +$3.70 million (+3.81%).
- PCRX quarterly accounts receivable is now -4.64% below its all-time high of $105.56 million, reached on December 31, 2023.
Performance
PCRX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
PCRX Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +7.3% | +3.8% |
| 3 y3 years | +99.0% | +9.3% |
| 5 y5 years | +177.8% | +9.3% |
PCRX Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +9.6% | -4.6% | +10.5% |
| 5 y | 5-year | at high | +122.1% | -4.6% | +158.2% |
| alltime | all time | at high | +8762.8% | -4.6% | >+9999.0% |
Pacira BioSciences Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $100.65 M(-3.9%) |
| Jun 2024 | - | $104.78 M(+3.1%) |
| Mar 2024 | - | $101.64 M(-3.7%) |
| Dec 2023 | $105.56 M(+7.3%) | $105.56 M(+8.9%) |
| Sep 2023 | - | $96.96 M(-2.1%) |
| Jun 2023 | - | $99.08 M(+6.3%) |
| Mar 2023 | - | $93.20 M(-5.3%) |
| Dec 2022 | $98.40 M(+2.2%) | $98.40 M(+5.3%) |
| Sep 2022 | - | $93.47 M(+2.6%) |
| Jun 2022 | - | $91.11 M(-1.1%) |
| Mar 2022 | - | $92.10 M(-4.4%) |
| Dec 2021 | $96.32 M(+81.6%) | $96.32 M(+92.7%) |
| Sep 2021 | - | $49.98 M(-26.9%) |
| Jun 2021 | - | $68.36 M(+30.0%) |
| Mar 2021 | - | $52.58 M(-0.9%) |
| Dec 2020 | $53.05 M(+11.6%) | $53.05 M(+15.0%) |
| Sep 2020 | - | $46.14 M(+4.8%) |
| Jun 2020 | - | $44.01 M(+12.9%) |
| Mar 2020 | - | $38.99 M(-18.0%) |
| Dec 2019 | $47.53 M(+25.1%) | $47.53 M(+11.6%) |
| Sep 2019 | - | $42.57 M(+3.5%) |
| Jun 2019 | - | $41.15 M(+3.5%) |
| Mar 2019 | - | $39.77 M(+4.6%) |
| Dec 2018 | $38.00 M(+20.0%) | $38.00 M(+10.9%) |
| Sep 2018 | - | $34.27 M(-3.9%) |
| Jun 2018 | - | $35.64 M(+14.2%) |
| Mar 2018 | - | $31.20 M(-1.4%) |
| Dec 2017 | $31.66 M | $31.66 M(+17.2%) |
| Sep 2017 | - | $27.02 M(-1.6%) |
| Jun 2017 | - | $27.47 M(-0.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2017 | - | $27.70 M(-7.5%) |
| Dec 2016 | $29.94 M(+15.8%) | $29.94 M(+11.9%) |
| Sep 2016 | - | $26.77 M(-6.6%) |
| Jun 2016 | - | $28.65 M(+10.6%) |
| Mar 2016 | - | $25.90 M(+0.2%) |
| Dec 2015 | $25.86 M(+15.6%) | $25.86 M(-0.2%) |
| Sep 2015 | - | $25.92 M(+6.7%) |
| Jun 2015 | - | $24.28 M(-0.9%) |
| Mar 2015 | - | $24.51 M(+9.6%) |
| Dec 2014 | $22.37 M(+53.3%) | $22.37 M(+9.0%) |
| Sep 2014 | - | $20.52 M(-0.1%) |
| Jun 2014 | - | $20.55 M(+28.7%) |
| Mar 2014 | - | $15.97 M(+9.5%) |
| Dec 2013 | $14.59 M(+235.2%) | $14.59 M(+49.3%) |
| Sep 2013 | - | $9.77 M(+26.0%) |
| Jun 2013 | - | $7.76 M(+47.9%) |
| Mar 2013 | - | $5.24 M(+20.5%) |
| Dec 2012 | $4.35 M(+106.0%) | $4.35 M(+77.0%) |
| Sep 2012 | - | $2.46 M(-23.5%) |
| Jun 2012 | - | $3.21 M(+273.7%) |
| Mar 2012 | - | $860.00 K(-59.3%) |
| Dec 2011 | $2.11 M(+77.4%) | $2.11 M(+41.2%) |
| Sep 2011 | - | $1.50 M(+41.8%) |
| Jun 2011 | - | $1.05 M(-41.7%) |
| Mar 2011 | - | $1.81 M(+52.0%) |
| Dec 2010 | $1.19 M(-18.1%) | $1.19 M(-52.9%) |
| Sep 2010 | - | $2.53 M(-22.2%) |
| Jun 2010 | - | $3.25 M(+123.7%) |
| Dec 2009 | $1.46 M(-43.7%) | $1.46 M |
| Dec 2008 | $2.58 M | - |
FAQ
- What is Pacira BioSciences annual accounts receivable?
- What is the all time high annual accounts receivable for Pacira BioSciences?
- What is Pacira BioSciences annual accounts receivable year-on-year change?
- What is Pacira BioSciences quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Pacira BioSciences?
- What is Pacira BioSciences quarterly accounts receivable year-on-year change?
What is Pacira BioSciences annual accounts receivable?
The current annual accounts receivable of PCRX is $105.56 M
What is the all time high annual accounts receivable for Pacira BioSciences?
Pacira BioSciences all-time high annual accounts receivable is $105.56 M
What is Pacira BioSciences annual accounts receivable year-on-year change?
Over the past year, PCRX annual accounts receivable has changed by +$7.16 M (+7.28%)
What is Pacira BioSciences quarterly accounts receivable?
The current quarterly accounts receivable of PCRX is $100.65 M
What is the all time high quarterly accounts receivable for Pacira BioSciences?
Pacira BioSciences all-time high quarterly accounts receivable is $105.56 M
What is Pacira BioSciences quarterly accounts receivable year-on-year change?
Over the past year, PCRX quarterly accounts receivable has changed by +$3.70 M (+3.81%)